Search En menu en ClientConnect
Search
Results
Top 5 search results See all results Advanced search
Top searches
Most visited pages

Signature(s)

Amount
€ 75,000,000
Countries
Sector(s)
France : € 10,500,000
Italy : € 64,500,000
Industry : € 75,000,000
Signature date(s)
30/11/2010 : € 10,500,000
30/11/2010 : € 64,500,000
Link to source
Other links
Summary sheet

Summary sheet

Release date
25 November 2009
Status
Reference
Signed | 30/11/2010
20090373
Project name
Promoter - financial intermediary
Recordati Group RDI

Recordati Industria Chimica e Farmaceutica S.p.A. (Recordati), an Italian pharmaceutical company, and its controlled companies.

Proposed EIB finance (Approximate amount)
Total cost (Approximate amount)
Up to EUR 55 million.
Estimated at EUR 113 million.
Location
Sector(s)
Description
Objectives

The project concerns investments in Research, Development and Innovation (RDI) related to the development of new drug entities within the cardiovascular and urogenital therapeutic areas, as well as the the development of new drugs for the treatment of rare diseases.

Further development of Recordati portfolio of pharmaceutical products to expand their field of application and enhance their performance.

Environmental aspects
Procurement

The R&D activities encompassed within this project will not materially change current R&D practices and will be carried out within existing facilities making use of existing laboratories. Thus an Environmental Impact Assessment (EIA) according to the EU Directive 97/11, as amended by Directive 2003/35, is not required.

Procurement is expected to be in line with EIB guidelines for private sector projects. The Bank’s services will verify details during the project’s due diligence.

Link to source
Summary sheet
Other links

Disclaimer

Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The information and data provided on this page are therefore indicative.
They are provided for transparency purposes only and cannot be considered to represent official EIB policy (see also the Explanatory notes).

General enquiries and comments

The EIB is committed to open communication and encourages constructive stakeholder input regarding its activities.
Enquiries and comments concerning the EIB’s involvement in a project or the financing facilities, activities, organisation and objectives of the EIB, can be sent to the EIB Infodesk.
Alternatively, the EIB can be contacted through its external offices.
Queries regarding details of a specific project, in particular when it is under appraisal by the EIB, should preferably be addressed directly to project promoters.

Media enquiries

Media-related enquiries can be addressed to the EIB Press Office. Please also visit our Media information section.

Complaints mechanism

Any complaint regarding alleged maladministration can be lodged via the EIB Complaints Mechanism. The European Ombudsman acts as an independent external accountability mechanism of the EIB.

Zero tolerance against fraud and corruption

The EIB has a zero tolerance policy on fraud or corruption. To report allegations of fraud and corruption relating to EIB-financed projects, please contact the Fraud and Investigation division. All complaints will be treated as strictly confidential and handled in line with the EIB investigation procedures and the Anti-Fraud Policy.

Related publications